Drug delivery specialist Aptar Pharma has announced a strategic three-year research collaboration with Macquarie University in Australia, aimed at optimizing the pulmonary delivery of complex biologic therapeutics. The partnership centers on Aptar’s proprietary Orbital dry powder inhaler (DPI) platform, a technology specifically engineered to handle high-payload dry powder formulations.
By uniting academic research excellence with industry-leading device design, the collaboration seeks to address some of the most persistent hurdles in modern pharmaceutical development: successfully translating the therapeutic potential of biologics into non-invasive, highly effective inhaled treatments. The initiative comes at a time when the pharmaceutical industry is increasingly looking toward pulmonary administration as a viable route for macromolecules, peptides, proteins, and other sensitive therapeutics that typically require parenteral administration.
Deconstructing the Science: Formulation Variables and Aerosol Performance
The core objective of the three-year research program is to evaluate how specific formulation variables influence aerosol performance when deployed through the Orbital DPI platform. Throughout the partnership, researchers at Macquarie University and Aptar will examine a wide spectrum of formulation types, including engineered, blended, and combined dry powders.
Understanding how these physical and chemical characteristics influence aerosol behavior and overall device performance is critical. When patients use a dry powder inhaler, the drug must successfully deagglomerate into respirable particles that can navigate the tortuous pathways of the human respiratory tract and reach the deep lung. By systematically analyzing these variables, the research team aims to generate empirical data that maps the complex interplay between formulation design and aerodynamic performance.
A significant outcome anticipated from this generated data is the advancement and refinement of computational fluid dynamics (CFD) models. CFD modeling utilizes numerical analysis and data structures to simulate fluid and particle interactions. In pulmonary drug delivery, advanced CFD models allow researchers to visualize and predict aerosol behavior and particle transport with high precision. By anchoring these computational models in robust physical data generated through the Macquarie partnership, scientists can accelerate the rational design of future inhalation products, reducing the trial-and-error burden historically associated with formulation development.
The Strategic Value of Pulmonary Delivery for Biologics
The physiological characteristics of the pulmonary system make it an exceptionally attractive route of administration for systemically acting drugs, including biologics. The lungs boast an expansive absorptive surface area—roughly estimated to be the size of a tennis court—coupled with an exceptionally thin alveolar-capillary membrane and a rich blood supply. This unique anatomical architecture facilitates the rapid absorption of therapeutics directly into the systemic circulation, bypassing the harsh enzymatic and acidic environment of the gastrointestinal tract and avoiding first-pass hepatic metabolism.
Despite these clear anatomical advantages, formulating biologics for inhalation presents formidable scientific challenges. Macromolecules such as proteins, monoclonal antibodies, and nucleic acids are inherently fragile. The mechanical shear forces experienced during aerosolization, coupled with environmental stressors like moisture and temperature fluctuations, can induce protein denaturation, aggregation, or loss of structural integrity.
Furthermore, many biologic therapies require high doses to achieve a therapeutic effect. Traditional dry powder inhalers often struggle with high payload delivery, as packing large amounts of powder into a single unit dose without compromising flow properties or deagglomeration efficiency is notoriously difficult. Aptar’s Orbital platform was specifically designed to overcome these high-payload limitations, making it a compelling vehicle for the biologic drugs being investigated in this new academic partnership.
Industry Perspectives and Official Commentary
Leadership from both collaborating entities have emphasized the strategic importance of bridging academic research and industrial application to solve translational roadblocks in drug delivery.
Guillaume Brouet, Aptar’s vice president of scientific affairs, highlighted the inherent difficulties of the field while underlining the transformative potential of the collaboration. "Biologic medicines represent a promising area of pharmaceutical development, yet significant challenges remain in translating their potential into effective inhaled therapies," Brouet stated. "By combining academic and industry expertise, this programme will help advance scientific understanding of high-dose dry powder delivery and support the development of future inhaled biologic medicines."
While specific financial terms of the three-year agreement have not been publicly disclosed, the institutional commitment signals a long-term strategic alignment. For Macquarie University, the partnership offers researchers access to cutting-edge industrial delivery platforms and commercial insights, ensuring that academic inquiries remain closely tied to real-world clinical and manufacturing requirements. For Aptar Pharma, collaborating with a top-tier research institution provides independent scientific validation, advanced analytical capabilities, and enhanced data generation to support its growing portfolio of inhalation technologies.
Expanding Footprint: Recent Strategic Moves by Aptar Pharma
The Macquarie University collaboration is part of a broader, aggressive expansion of Aptar’s inhalation development capabilities. The announcement arrives closely on the heels of another major strategic partnership unveiled earlier in the month, further cementing Aptar’s position as a dominant force in advanced pulmonary and nasal drug delivery solutions.
Earlier in September, Aptar announced a collaborative agreement with French biotechnology firm Aceso Therapeutics. Under the terms of that arrangement, Aptar is supporting Aceso in the pre-clinical and clinical advancement of ACT-101, an innovative inhalable antisense oligonucleotide (ASO) designed to target the underlying disease mechanisms of cystic fibrosis (CF).
Cystic fibrosis is a debilitating genetic disorder characterized by the accumulation of thick, sticky mucus in the lungs, predisposing patients to chronic bacterial infections and progressive respiratory failure. Inhalable ASO therapies offer a localized approach to downregulate disease-causing genes directly within the pulmonary epithelium. However, delivering oligonucleotides efficiently to the lungs requires specialized formulation and delivery expertise.
To support Aceso’s clinical development roadmap for ACT-101, Aptar is leveraging Nanopharm, its specialized inhalation development services business. Acquired by Aptar in 2019, Nanopharm provides advanced materials science characterization, analytical testing, and expert formulation development services for orally inhaled and nasal drug products (OINDPs). Nanopharm’s integration into Aptar’s broader corporate ecosystem allows the company to offer an end-to-end service model—guiding pharmaceutical clients from early-stage feasibility studies and formulation optimization all the way through to commercial device manufacturing.
Timeline and Chronological Context
The formalization of the Macquarie University partnership follows a steady cadence of strategic investments by Aptar Pharma into targeted respiratory delivery systems:
- Late 2019: Aptar acquires Nanopharm, significantly strengthening its internal capabilities in advanced aerosol characterization and inhalation product development.
- Early September: Aptar announces its collaboration with Aceso Therapeutics to support the development of the inhalable antisense oligonucleotide ACT-101 for cystic fibrosis via its Nanopharm division.
- Mid-to-Late September: Aptar officially enters its three-year research partnership with Macquarie University to investigate formulation variables and aerosol performance using the Orbital dry powder inhaler platform.
- 2026–2029: The duration of the Macquarie University research initiative, during which iterative testing, formulation evaluations, and computational fluid dynamics model developments are slated to occur.
Broader Implications for the Pharmaceutical Industry
The convergence of biologic drugs and advanced inhalation devices represents a major frontier in modern therapeutics. As the global pharmaceutical pipeline shifts increasingly toward targeted biologics, gene therapies, and nucleic acid-based medicines, the reliance on injectable and infusion-based delivery routes poses ongoing challenges regarding patient compliance, healthcare resource utilization, and patient quality of life.
Inhaled biologics offer a compelling alternative, promising non-invasive administration, self-management capabilities, and improved localized therapeutic concentrations for respiratory conditions. However, realizing this promise requires robust interdisciplinary cooperation. The partnership between Aptar Pharma and Macquarie University exemplifies the type of targeted, mechanism-driven research required to decode the complexities of powder behavior, device aerodynamics, and biological interaction.
As the three-year program progresses, the data generated by the partnership is expected to yield valuable insights not only for Aptar’s proprietary Orbital platform, but for the broader OINDP sector. By establishing clearer correlations between formulation variables and aerosol performance—and by hardening computational fluid dynamics models against empirical benchmarks—the initiative could substantially lower development barriers for future inhaled biologic drugs. Ultimately, these scientific advancements move the pharmaceutical industry closer to a reality where complex macromolecules can be routinely and reliably delivered via simple, patient-friendly inhaler devices.
